![]()
Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (+)-schisandrin B | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC35E2B mRNA] | CTD | PMID:31150632 | (1->4)-beta-D-glucan | multiple interactions | ISO | RGD:1319215 | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of SLC35E2 mRNA | CTD | PMID:36331819 | 1,2-dimethylhydrazine | decreases expression | ISO | RGD:1319215 | 6480464 | 1, 2-Dimethylhydrazine results in decreased expression of SLC35E2 mRNA | CTD | PMID:22206623 | 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of SLC35E2B mRNA | CTD | PMID:29097150 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1319215 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of SLC35E2 mRNA | CTD | PMID:19770486 | 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of SLC35E2B mRNA | CTD | PMID:32109520 | 3,4-methylenedioxymethamphetamine | increases expression | ISO | RGD:1319215 | 6480464 | N-Methyl-3, 4-methylenedioxyamphetamine results in increased expression of SLC35E2 mRNA | CTD | PMID:20188158, PMID:26251327 | 3-isobutyl-1-methyl-7H-xanthine | multiple interactions | ISO | RGD:4109106 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SLC35E2B mRNA | CTD | PMID:28628672 | 4-hydroxyphenyl retinamide | increases expression | ISO | RGD:1319215 | 6480464 | Fenretinide results in increased expression of SLC35E2B mRNA | CTD | PMID:28973697 | acetamide | decreases expression | EXP | | 6480464 | acetamide results in decreased expression of SLC35E2B mRNA | CTD | PMID:31881176 | acrylamide | increases expression | EXP | | 6480464 | Acrylamide results in increased expression of SLC35E2B mRNA | CTD | PMID:28959563 | aflatoxin B1 | increases methylation | ISO | RGD:4109106 | 6480464 | Aflatoxin B1 results in increased methylation of SLC35E2B gene | CTD | PMID:27153756 | benzo[a]pyrene | increases methylation | ISO | RGD:4109106 | 6480464 | Benzo(a)pyrene results in increased methylation of SLC35E2 5' UTR | CTD | PMID:27901495 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of SLC35E2B mRNA | CTD | PMID:25181051 | bisphenol A | decreases expression | ISO | RGD:1319215 | 6480464 | bisphenol A results in decreased expression of SLC35E2 mRNA | CTD | PMID:32156529 | bisphenol A | increases expression | ISO | RGD:4109106 | 6480464 | bisphenol A results in increased expression of SLC35E2 mRNA | CTD | PMID:29275510 | bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of SLC35E2B mRNA | CTD | PMID:29097150 | bisphenol F | multiple interactions | ISO | RGD:4109106 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SLC35E2B mRNA | CTD | PMID:28628672 | butanal | decreases expression | ISO | RGD:4109106 | 6480464 | butyraldehyde results in decreased expression of SLC35E2B mRNA | CTD | PMID:26079696 | cadmium atom | multiple interactions | ISO | RGD:4109106 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC35E2B mRNA | CTD | PMID:35301059 | cadmium dichloride | multiple interactions | ISO | RGD:4109106 | 6480464 | [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC35E2B mRNA | CTD | PMID:35301059 | chromium(6+) | affects expression | ISO | RGD:1319215 | 6480464 | chromium hexavalent ion affects the expression of SLC35E2 mRNA | CTD | PMID:28472532 | clofibrate | decreases expression | ISO | RGD:1319215 | 6480464 | Clofibrate results in decreased expression of SLC35E2 mRNA | CTD | PMID:23811191 | crocidolite asbestos | decreases expression | ISO | RGD:1319215 | 6480464 | Asbestos, Crocidolite results in decreased expression of SLC35E2 mRNA | CTD | PMID:29279043 | cyclosporin A | decreases expression | ISO | RGD:1319215 | 6480464 | Cyclosporine results in decreased expression of SLC35E2 mRNA | CTD | PMID:19770486 | dexamethasone | multiple interactions | ISO | RGD:4109106 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SLC35E2B mRNA | CTD | PMID:28628672 | dibutyl phthalate | decreases expression | ISO | RGD:1319215 | 6480464 | Dibutyl Phthalate results in decreased expression of SLC35E2 mRNA | CTD | PMID:21266533 | dicrotophos | increases expression | ISO | RGD:4109106 | 6480464 | dicrotophos results in increased expression of SLC35E2B mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | RGD:4109106 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35E2B mRNA | CTD | PMID:27188386 | epoxiconazole | increases expression | ISO | RGD:1319215 | 6480464 | epoxiconazole results in increased expression of SLC35E2 mRNA | CTD | PMID:35436446 | fenthion | decreases expression | ISO | RGD:1319215 | 6480464 | Fenthion results in decreased expression of SLC35E2 mRNA | CTD | PMID:34813904 | folic acid | increases expression | ISO | RGD:1319215 | 6480464 | Folic Acid results in increased expression of SLC35E2 mRNA | CTD | PMID:25629700 | gallic acid | decreases expression | ISO | RGD:4109106 | 6480464 | Gallic Acid results in decreased expression of SLC35E2B mRNA | CTD | PMID:34408198 | indometacin | multiple interactions | ISO | RGD:4109106 | 6480464 | [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in decreased expression of SLC35E2B mRNA | CTD | PMID:28628672 | leflunomide | decreases expression | ISO | RGD:4109106 | 6480464 | leflunomide results in decreased expression of SLC35E2B mRNA | CTD | PMID:28988120 | paracetamol | decreases expression | ISO | RGD:4109106 | 6480464 | Acetaminophen results in decreased expression of SLC35E2B mRNA | CTD | PMID:21420995 | paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of SLC35E2B mRNA | CTD | PMID:33387578 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | RGD:1319215 | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in decreased expression of SLC35E2 mRNA | CTD | PMID:36331819 | pirinixic acid | decreases expression | ISO | RGD:1319215 | 6480464 | pirinixic acid results in decreased expression of SLC35E2 mRNA | CTD | PMID:23811191 | SB 431542 | multiple interactions | ISO | RGD:4109106 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35E2B mRNA | CTD | PMID:27188386 | sunitinib | increases expression | ISO | RGD:4109106 | 6480464 | Sunitinib results in increased expression of SLC35E2B mRNA | CTD | PMID:31533062 | tetrachloromethane | decreases expression | EXP | | 6480464 | Carbon Tetrachloride results in decreased expression of SLC35E2B mRNA | CTD | PMID:31150632 | tetrachloromethane | decreases expression | ISO | RGD:1319215 | 6480464 | Carbon Tetrachloride results in decreased expression of SLC35E2 mRNA | CTD | PMID:31919559 | tetrachloromethane | multiple interactions | EXP | | 6480464 | schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC35E2B mRNA] | CTD | PMID:31150632 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of SLC35E2B mRNA | CTD | PMID:34492290 | valproic acid | increases methylation | ISO | RGD:4109106 | 6480464 | Valproic Acid results in increased methylation of SLC35E2B gene | CTD | PMID:29154799 | valproic acid | decreases expression | ISO | RGD:4109106 | 6480464 | Valproic Acid results in decreased expression of SLC35E2B mRNA | CTD | PMID:23179753 more ... | valproic acid | multiple interactions | ISO | RGD:4109106 | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC35E2B mRNA | CTD | PMID:27188386 | valproic acid | affects expression | ISO | RGD:1319215 | 6480464 | Valproic Acid affects the expression of SLC35E2 mRNA | CTD | PMID:17292431 | |